美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

赛博科技

0.3100

+0.0000

成交量：- -

成交额：- -

市值：2,531.03万

市盈率：-0.15

高：0.3100

开：0.3100

低：0.3100

收：0.3100

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

Camizestrant与芙仕得相比显著延缓晚期ER阳性乳腺癌患者疾病进展，延长至少3.5个月患者获益

KN046联合白蛋白紫杉醇用于三阴乳腺癌治疗的最终研究结果在SABCS 2022公布

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CBR"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CBR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CBR\",,,,,undefined,":{"symbol":"CBR","market":"US","secType":"STK","nameCN":"赛博科技","latestPrice":0.31,"timestamp":1499101200000,"preClose":0.31,"halted":0,"volume":0,"delay":0,"floatShares":71806040,"shares":81646000,"eps":-2.1,"marketStatus":"盘前交易","change":0,"latestTime":"04-25 06:25:00 EDT","open":0.31,"high":0.31,"low":0.31,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.1,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"listingDate":763880400000,"exchange":"NYSE","adjPreClose":0.31,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CBR\",,,,,undefined,":{"symbol":"CBR","floatShares":71806040,"roa":"--","roe":"--","lyrEps":0,"shares":81646000,"dividePrice":0,"high":0.31,"amplitude":0,"preClose":0.31,"low":0.31,"week52Low":0.22,"pbRate":"0.16","week52High":2.36,"institutionHeld":0.7701,"latestPrice":0.31,"eps":-2.1,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.1,"open":0.31,"prevYearClose":0.31},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CBR\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CBR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2290707862","title":"Camizestrant与芙仕得相比显著延缓晚期ER阳性乳腺癌患者疾病进展，延长至少3.5个月患者获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2290707862","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290707862?lang=zh_cn&edition=fundamental","pubTime":"2022-12-12 12:57","pubTimestamp":1670821020,"startTime":"0","endTime":"0","summary":"Camizestrant在没有检测到ESR1突变的患者中也有疗效，75mg和150mg剂量水平下疾病进展或死亡风险分别降低22%和24%。Camizestrant的耐受性普遍良好，其安全性与以前的试验中观察到的一致，没有发现新的安全信号。阿斯利康为评估Camizestrant治疗晚期乳腺癌制定了广泛的临床开发计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3962076_ZH62076_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4023","HR","LU0320765992.SGD","PFS","BK4195","CBR","BK4568","CDK","BK4203","AZN","LU0889565916.HKD","LU0109394709.USD","BK4007"],"gpt_icon":0},{"id":"2290748162","title":"KN046联合白蛋白紫杉醇用于三阴乳腺癌治疗的最终研究结果在SABCS 2022公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2290748162","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290748162?lang=zh_cn&edition=fundamental","pubTime":"2022-12-12 10:30","pubTimestamp":1670812200,"startTime":"0","endTime":"0","summary":"KN046-203的初步研究结果已于2021年在AACR大会线上公开，本次公开的数据是该研究的最终研究结果。研究结果表明，KN046耐受性良好；KN046联合白蛋白结合型紫杉醇对晚期三阴乳腺癌患者有效，无论患者的PD-L1是否阳性，都显示出无进展生存期和总生存期获益。目前KN046四个注册临床试验正在进行中，其中KN046联合化疗一线治疗非小细胞肺癌的Ⅲ期临床研究中期分析成功达到预设PFS终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3962192_ZH62192_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE0004445015.USD","BK4512","BK4573","LU0198837287.USD","LU0234572021.USD","IE00B19Z9505.USD","BK4161","BK1574","BK4571","LU0109391861.USD","LU0417517546.SGD","BK4566","IE0009356076.USD","LU0456855351.SGD","BK4532","IE00BJJMRY28.SGD","LU0256863811.USD","09966","BK4576","LU0149725797.USD","BK4581","BK4574","LU0353189680.USD","BK4533","IE00B1XK9C88.USD","BK4170","IE00BJTD4V19.USD","LU0097036916.USD","ITT","LU0056508442.USD","LU0444971666.USD","IE00B3S45H60.SGD","BK4550","IE00BJJMRX11.SGD","BK4534","LU0109392836.USD","BK4575","LU0353189763.USD","IE00BSNM7G36.USD","LU0320765059.SGD","LU0289739343.SGD","IRC","IE00B1BXHZ80.USD","BK4553","CBR","BK4195","BK4515","LU0511384066.AUD","BK4527","IE0004445239.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CBR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-08","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":-0.06,"name":null,"time":"盘前","type":"earning","dateTimestamp":1478581200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-08-04","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":-0.02,"name":null,"time":"盘前","type":"earning","dateTimestamp":1470283200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-05","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":-0.13,"name":null,"time":"盘前","type":"earning","dateTimestamp":1462420800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-02-18","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":0.04,"name":null,"time":"盘前","type":"earning","dateTimestamp":1455771600000,"reportTimeType":"pre","actualEps":0.01},{"market":"US","date":"2015-10-29","symbol":"CBR","fiscalQuarterEnding":null,"expectedEps":0.03,"name":null,"time":"盘前","type":"earning","dateTimestamp":1446091200000,"reportTimeType":"pre","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CBR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CBR\",market:\"US\",delay:false,,,undefined,":{}}}